Envoy Medical, Inc.
No SEC Form 4 filings for $COCH in the last 30 days.
See all $COCH insider activity →Envoy Medical, Inc. (COCH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030137201ex99-1.htm PRESS RELEASE DATED AUGUST 10, 2026 Exhibit 99.1 Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company R
Envoy Medical (NASDAQ: COCH) said it has passed the three-month visit milestone for all 56 patients in its pivotal trial of the investigational fully implanted Acclaim cochlear implant. The company continues collecting safety and study measures for a planned FDA PMA submission. It expects six-month enrollment by late 2026 and 12-month study data by April 2027.
Envoy Medical (NASDAQ: COCH) reported positive 12-month interim results from Stage 1 of its pivotal trial for the investigational fully implanted Acclaim cochlear implant. In 10 participants, mean CNC word recognition rose to 53.2% from a 15.2% baseline. No protocol-defined serious adverse events were reported. Stage 2 is fully enrolled.
Over the past 7 days, alphai's AI scored 1 news story mentioning COCH (Envoy Medical, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent COCH coverage spans financial news, corporate actions and technology.
Regulatory and clinical progress increases the probability of eventual PMA acceptance and de-risks the timeline toward a 2027 final module submission.
Clinical-trial execution milestone reduces near-term execution risk and supports the company’s stated path to PMA submission, but it is not yet regulatory approval.
Positive 12-month efficacy readout and no protocol-defined SAEs reduce perceived clinical risk for Acclaim, supporting a more constructive FDA-PMA outlook.
The OFS at a discounted floor price creates near-term supply/dilution overhang and caps upside expectations for the open-market price.
A government OFS of 2.52% base plus 2.52% greenshoe can pressure near-term liquidity/float and sentiment, especially given the stated discount.
alphai scores every news story that mentions COCH with an AI model for sentiment and relevance, and aggregates insider trades from Envoy Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Envoy Medical, Inc. (COCH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030137201ex99-1.htm PRESS RELEASE DATED AUGUST 10, 2026 Exhibit 99.1 Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company R
6 min readEnvoy Medical (NASDAQ: COCH) said it has passed the three-month visit milestone for all 56 patients in its pivotal trial of the investigational fully implanted Acclaim cochlear implant. The company continues collecting safety and study measures for a planned FDA PMA submission. It expects six-month enrollment by late 2026 and 12-month study data by April 2027.
2 min readEnvoy Medical (NASDAQ: COCH) reported positive 12-month interim results from Stage 1 of its pivotal trial for the investigational fully implanted Acclaim cochlear implant. In 10 participants, mean CNC word recognition rose to 53.2% from a 15.2% baseline. No protocol-defined serious adverse events were reported. Stage 2 is fully enrolled.
4 min readCochin Shipyard shares fell 4.1% to ₹1,445.1 on Tuesday after India’s government announced an Offer for Sale of up to 5.04% of its stake at a floor price of ₹1,400, a >7% discount to the prior day. The OFS supply weighed on the stock; government holds 67.92%.
3 min readIndia’s Department of Investment and Public Asset Management said the government will sell up to 5.04% of its stake in Cochin Shipyard via an offer for sale. The base sale is 2.52% with an option for another 2.52% if oversubscribed. The floor price is 1,400 rupees/share, a >7% discount to the last close. Non-retail opens Tuesday; retail Wednesday.
2 min readEnvoy Medical, Inc. (COCH) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0001840877 0001840877 2026-06-24 2026-06-24 0001840877 COCH:ClassCommonStockParValue0.0001PerShareMember 2026-06-24 2026-06-24 0001840877 COCH:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2026-06-24 2026-06-2
2 min readA lock-up agreement applies to 28,934,960 Class A Common Stock of Envoy Medical, Inc., starting from February 12, 2026, and ending on April 13, 2026. This agreement restricts executive officers and directors from selling or offering these shares for 60 days following the offering's closing, with customary exceptions for existing stock option plans.
2 min readKeybanc analyst Sophie Karp initiated coverage on NiSource Inc. (NYSE: NI) with an Overweight rating and a price target of $52. Additionally, BTIG analyst Marie Thibault began coverage on Minimed Group, Inc. (NASDAQ: MMED) with a Buy rating and a $25 price target, and HC Wainwright & Co. analyst Yi Chen initiated coverage on Envoy Medical, Inc. (NASDAQ: COCH) with a Buy rating and a $2.5 price target. These inaugurate Tuesday's top analyst initiations, reflecting bullish outlooks for the respective companies.
3 min readEnvoy Medical, Inc. (NASDAQ: COCH) specializes in fully implanted hearing devices, including the FDA-approved Esteem® FI-AMEI for moderate to severe sensorineural hearing loss and the investigational Acclaim® cochlear implant, which has FDA Breakthrough Device Designation and is in a pivotal clinical trial. The company emphasizes its pioneering role in fully implanted hearing technology, an expanding patent portfolio, and a business model combining commercial sales with ongoing clinical development and capital raising activities. Financial highlights show significant R&D investment and net losses, with upcoming regulatory and financial milestones.
3 min readEnvoy Medical, Inc. (COCH) delivered earnings and revenue surprises of -29.63% and -23.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
